<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e>-specific hypermethylation of (promoter) CpG islands is common during the <z:mp ids='MP_0002006'>tumorigenesis</z:mp> of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although associations between certain genetic aberrations, such as BRAF mutation and microsatellite instability, and the CpG island methylator phenotype (CIMP), have been found, the mechanisms by which these associations are established are still unclear </plain></SENT>
<SENT sid="2" pm="."><plain>We studied genome-wide DNA methylation differences between <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> carrying a BRAF mutation and BRAF <z:mp ids='MP_0002169'>wildtype</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Using differential methylation hybridization on oligonucleotide microarrays representing 32,171 CpG-rich regions, we identified 1,770 regions with differential methylation between <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> and paired <z:mpath ids='MPATH_458'>normal</z:mpath> colon </plain></SENT>
<SENT sid="4" pm="."><plain>Next, we compared the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>/<z:mpath ids='MPATH_458'>normal</z:mpath> methylation ratios between different groups of patients </plain></SENT>
<SENT sid="5" pm="."><plain>Related to CIMP, we identified 749 differentially methylated regions, of which 86% had a higher <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>/<z:mpath ids='MPATH_458'>normal</z:mpath> methylation ratio in the CIMP-positive group </plain></SENT>
<SENT sid="6" pm="."><plain>We identified 758 regions with a BRAF mutation-specific methylation change, of which 96% had a higher <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>/<z:mpath ids='MPATH_458'>normal</z:mpath> methylation ratio in the BRAF mutant group </plain></SENT>
<SENT sid="7" pm="."><plain>Among the genes affected by BRAF mutation-specific methylation changes, we found enrichment of several <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related pathways, including the PI3 kinase and Wnt signaling pathways </plain></SENT>
<SENT sid="8" pm="."><plain>To focus on genes that are silenced in a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific rather than a lineage-specific manner, we used information on the epigenetic silencing mark H3K27me3 in embryonic stem (ES) cells </plain></SENT>
<SENT sid="9" pm="."><plain>Among the genes showing BRAF mutation-specific promoter methylation but no H3K27me3 mark in ES cells were forkhead box (FOX) transcription factors associated with the PI3 kinase pathway, as well as MLH1 and SMO </plain></SENT>
<SENT sid="10" pm="."><plain>Repression of FOXD3 gene expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> could be related to its promoter hypermethylation </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: We identified new BRAF mutation-specific methylation changes in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Epigenetic downregulation of these targets may contribute to mutationally active BRAF-driven <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, explaining its association with aberrant DNA methylation </plain></SENT>
</text></document>